Siamak Mohammadkhani Shali1, Vanessa Schmitt2, Florian F Behrendt1, Oliver H Winz1, Alexander Heinzel1, Felix M Mottaghy3, Michael J Eble2, Frederik A Verburg4. 1. RWTH Aachen University Hospital, Departments of Nuclear Medicine, Germany. 2. RWTH Aachen University Hospital, Departments of Radiation therapy and Radiooncology, Germany. 3. RWTH Aachen University Hospital, Departments of Nuclear Medicine, Germany; Maastricht UMC+, Deparment of Nuclear Medicine, Maastricht, The Netherlands, The Netherlands. 4. RWTH Aachen University Hospital, Departments of Nuclear Medicine, Germany; Maastricht UMC+, Deparment of Nuclear Medicine, Maastricht, The Netherlands, The Netherlands. Electronic address: fverburg@ukaachen.de.
Abstract
AIM: to determine whether [(18)F]2-fluoro-2-deoxyglucose (FDG) positron emission tomography and X-ray computed tomography (PET/CT) findings and metabolic parameters before combined chemo- and radiotherapy (CRT) have a prognostic value in patients with anal carcinoma. MATERIALS AND METHODS: 45 patients with anal cancer who underwent pre-treatment FDG-PET/CT were included. Metabolic parameters, recurrence and anal carcinoma specific survival were analyzed. RESULTS: SUV max and metabolic volume of the primary tumour were significantly higher in patients with lymph node or distant metastases than in those with locally confined disease (p=0.020 and p=0.015, respectively). The extent of disease (local tumour only, lymph node or distant metastases) was highly predictive of both for recurrence free and disease specific survival (p=0.010 and p<0.001, respectively). Recurrence free (p=0.010) and anal carcinoma specific survival (p=0.006) differed significantly between patients with a metabolic volume ≤45ml and >45ml. Multivariate analysis revealed that a metabolic volume >45ml was the only significant independent determinant (p=0.19) for recurrence free survival whereas for anal carcinoma specific survival the extent of disease was identified as the only significant independent determinant (p=0.002). CONCLUSIONS: the extent of disease on FDG PET/CT before combined radio-chemotherapy is strongly predictive of prognosis in anal cancer. Furthermore, patients with a large metabolic volume of the primary tumour (>45ml) are at significantly higher risk of recurrence.
AIM: to determine whether [(18)F]2-fluoro-2-deoxyglucose (FDG) positron emission tomography and X-ray computed tomography (PET/CT) findings and metabolic parameters before combined chemo- and radiotherapy (CRT) have a prognostic value in patients with anal carcinoma. MATERIALS AND METHODS: 45 patients with anal cancer who underwent pre-treatment FDG-PET/CT were included. Metabolic parameters, recurrence and anal carcinoma specific survival were analyzed. RESULTS: SUV max and metabolic volume of the primary tumour were significantly higher in patients with lymph node or distant metastases than in those with locally confined disease (p=0.020 and p=0.015, respectively). The extent of disease (local tumour only, lymph node or distant metastases) was highly predictive of both for recurrence free and disease specific survival (p=0.010 and p<0.001, respectively). Recurrence free (p=0.010) and anal carcinoma specific survival (p=0.006) differed significantly between patients with a metabolic volume ≤45ml and >45ml. Multivariate analysis revealed that a metabolic volume >45ml was the only significant independent determinant (p=0.19) for recurrence free survival whereas for anal carcinoma specific survival the extent of disease was identified as the only significant independent determinant (p=0.002). CONCLUSIONS: the extent of disease on FDG PET/CT before combined radio-chemotherapy is strongly predictive of prognosis in anal cancer. Furthermore, patients with a large metabolic volume of the primary tumour (>45ml) are at significantly higher risk of recurrence.
Authors: Ahmed Allam Mohamed; Marsha Schlenter; Alexander Heinzel; Svetlana Kintsler; Michael J Eble Journal: Front Oncol Date: 2022-05-26 Impact factor: 5.738
Authors: P J Brown; J Zhong; R Frood; S Currie; A Gilbert; A L Appelt; D Sebag-Montefiore; A Scarsbrook Journal: Eur J Nucl Med Mol Imaging Date: 2019-09-04 Impact factor: 9.236
Authors: Hema Sekhar; Rohit Kochhar; Bernadette Carrington; Thomas Kaye; Damian Tolan; Mark P Saunders; Matthew Sperrin; David Sebag-Montefiore; Marcel van Herk; Andrew G Renehan Journal: BMC Cancer Date: 2020-11-30 Impact factor: 4.430